IRIS
MORABITO, FORTUNATO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.905
NA - Nord America 1.829
EU - Europa 964
SA - Sud America 821
AF - Africa 120
OC - Oceania 6
AN - Antartide 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.647
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.689
SG - Singapore 1.036
BR - Brasile 604
CN - Cina 582
VN - Vietnam 491
IT - Italia 434
HK - Hong Kong 238
BD - Bangladesh 160
FR - Francia 108
DE - Germania 107
AR - Argentina 75
KR - Corea 68
FI - Finlandia 66
IN - India 57
MX - Messico 52
GB - Regno Unito 47
IQ - Iraq 46
CA - Canada 45
RU - Federazione Russa 38
ZA - Sudafrica 34
EC - Ecuador 33
NL - Olanda 30
PK - Pakistan 30
CO - Colombia 28
ID - Indonesia 28
UA - Ucraina 25
AT - Austria 24
TR - Turchia 21
UZ - Uzbekistan 21
VE - Venezuela 21
PY - Paraguay 17
CL - Cile 15
DZ - Algeria 14
JP - Giappone 14
PL - Polonia 14
SA - Arabia Saudita 14
MY - Malesia 13
PH - Filippine 13
PE - Perù 12
ES - Italia 11
KE - Kenya 11
MA - Marocco 11
CR - Costa Rica 10
EG - Egitto 10
TN - Tunisia 10
AE - Emirati Arabi Uniti 9
ET - Etiopia 9
JO - Giordania 9
NP - Nepal 8
PA - Panama 8
UY - Uruguay 8
BO - Bolivia 7
KG - Kirghizistan 7
CZ - Repubblica Ceca 6
SN - Senegal 6
TT - Trinidad e Tobago 6
DO - Repubblica Dominicana 5
IL - Israele 5
OM - Oman 5
RO - Romania 5
SE - Svezia 5
AL - Albania 4
AZ - Azerbaigian 4
BA - Bosnia-Erzegovina 4
BG - Bulgaria 4
CH - Svizzera 4
KZ - Kazakistan 4
NI - Nicaragua 4
RS - Serbia 4
AU - Australia 3
BE - Belgio 3
BY - Bielorussia 3
GT - Guatemala 3
JM - Giamaica 3
LB - Libano 3
LY - Libia 3
PS - Palestinian Territory 3
SC - Seychelles 3
TW - Taiwan 3
BN - Brunei Darussalam 2
DK - Danimarca 2
GA - Gabon 2
HN - Honduras 2
IE - Irlanda 2
LT - Lituania 2
MK - Macedonia 2
NG - Nigeria 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
QA - Qatar 2
TH - Thailandia 2
AM - Armenia 1
AQ - Antartide 1
BH - Bahrain 1
BS - Bahamas 1
BW - Botswana 1
CI - Costa d'Avorio 1
GY - Guiana 1
HR - Croazia 1
HU - Ungheria 1
Totale 6.630
Salva come PNG Salva come JPEG
Città #
Singapore 443
San Jose 288
Hong Kong 237
Dallas 233
Ashburn 222
Ho Chi Minh City 173
Florence 155
Boardman 143
Council Bluffs 113
Beijing 112
Hefei 112
Hanoi 101
Lauterbourg 67
Seoul 67
São Paulo 61
Los Angeles 49
Munich 48
Shanghai 48
New York 46
Helsinki 43
Milan 27
Santa Clara 27
Da Nang 26
Rio de Janeiro 25
Haiphong 24
Sesto Fiorentino 23
Noto 22
Rome 21
Baghdad 20
Washington 20
Guangzhou 19
Quito 19
Montreal 17
Tashkent 17
Mexico City 15
The Dalles 15
Brooklyn 14
Naples 13
Orem 13
Vienna 13
Biên Hòa 12
Buffalo 12
Johannesburg 12
Turku 12
Amsterdam 11
Atlanta 11
Nairobi 11
Ogden 11
Tokyo 11
Warsaw 11
Brasília 10
Caracas 10
Lahore 10
Lappeenranta 10
Nuremberg 10
Phoenix 10
Addis Ababa 9
Amman 9
Belo Horizonte 9
Catania 9
Charlotte 9
Chicago 9
Dhaka 9
Frankfurt am Main 9
Guayaquil 9
Hillsboro 9
Karachi 9
Ninh Bình 9
Ribeirão Preto 9
Thái Nguyên 9
Wuhan 9
Bari 8
Boston 8
Chennai 8
Fortaleza 8
Kuala Lumpur 8
London 8
Mumbai 8
Buenos Aires 7
Campinas 7
Can Tho 7
Curitiba 7
Hangzhou 7
Medellín 7
Naaldwijk 7
New Delhi 7
San José 7
Bishkek 6
Bogotá 6
Cape Town 6
Dakar 6
Denver 6
Duhok 6
Erbil 6
Falkenstein 6
Kyiv 6
Paris 6
Portland 6
Porto Alegre 6
Recife 6
Totale 3.657
Salva come PNG Salva come JPEG
Nome #
Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options? 176
Vaccination in Multiple Myeloma: Challenges and Strategies 132
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 128
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 126
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study 124
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 123
Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy 122
Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma 120
Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter? 120
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 116
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 116
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 116
Momelotinib in myelofibrosis 115
Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives 110
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 110
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 109
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 108
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study 108
TP53‐Mutated Acute Myeloid Leukemia: Unanswered Questions 108
Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair? 106
MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells 105
Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients 105
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 105
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data 103
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials 103
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 102
The role of corticosteroids in the current treatment paradigm for myelofibrosis 99
Belantamab mafodotin in multiple myeloma 98
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study 93
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 93
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study 93
Iron chelation therapy 92
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities 91
Teclistamab-cqyv in multiple myeloma 91
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 90
LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells 89
Selinexor in multiple myeloma 89
Acalabrutinib in chronic lymphocytic leukemia 89
Comparative Analysis of Bispecific Antibodies and CAR T‐Cell Therapy in Follicular Lymphoma 88
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 87
Elotuzumab in multiple myeloma 87
Frailty predicts treatment-related toxicity and discontinuation in older adults with chronic lymphocytic leukemia treated with BTK and BCL-2 inhibitors: Findings from a prospective single-center cohort study 84
Myelodysplastic syndromes with ring sideroblasts 83
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort 82
Ivosidenib in acute myeloid leukemia 81
Rilzabrutinib for the Treatment of Immune Thrombocytopenia 80
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature 80
Avatrombopag for the Treatment of Immune Thrombocytopenia 78
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 78
Early progression beyond first‐line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study 73
Advances and Challenges in Quizartinib‐Based FLT3 Inhibition for Acute Myeloid Leukemia: Mechanisms of Resistance and Prospective Combination Therapies 73
REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA 70
Glasdegib for the treatment of acute myeloid leukemia 69
Zanubrutinib for the treatment of chronic lymphocytic leukemia 69
Maintenance therapy after ASCT in newly diagnosed multiple myeloma patients: single agent versus combination drugs 68
Therapy‐Related Acute Promyelocytic Leukemia: Case Series and Current Insights 67
Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity 67
Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura 65
Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions 65
Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications 64
Treatment-Free Remission in Chronic Myeloid Leukemia: Revisiting the "W" Questions 62
Mosunetuzumab for the treatment of follicular lymphoma 60
Potential of BGB-1417, a BCL2 inhibitor, in hematological malignancies 59
TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia 56
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens 55
Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents 51
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies 48
Isatuximab in multiple myeloma 48
Venetoclax in acute myeloid leukemia 48
The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia 44
T‐Cell–Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions 43
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study 41
Herpes Zoster in Hematological Disorders: Pathogenesis, Risk Stratification, and Emerging Strategies for Prevention and Immunization 35
Real‐World Evaluation of Oral Decitabine/Cedazuridine in Elderly Patients With Acute Myeloid Leukemia 33
Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy 28
Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies 25
Chemotherapy‐Sparing Strategies in Follicular Lymphoma: Emerging Targeted and Immune‐Based Approaches 24
Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort 22
Management of Primary Refractory Diffuse Large B‐Cell Lymphoma in Patients Unsuitable for CAR T‐Cell Therapy 20
Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies 18
Relapse Despite MRD Negativity in Multiple Myeloma: Toward Integrated Risk Prediction 17
Targeting the Menin– KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation 15
Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials 15
Reshaping multiple myeloma treatment: recent breakthroughs 14
Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integration 14
Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions 13
Ph‐Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs 12
Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM 11
Therapeutic Strategies for Relapsed or Refractory B‐Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies 11
Immunogenetic Architecture of Chronic Lymphocytic Leukemia at Early Stage: Insights from the O-CLL1 Cohort 8
Intraclonal Enrichment of IL-23 Receptor Complex Expression in the Proliferative Fraction of Chronic Lymphocytic Leukemia 8
Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives 7
What Does It Really Mean to Say That a Patient With a Hematologic Malignancy Is “Cured”? 4
Regional Standardization of CLL Management: Results of a Delphi Consensus Process 4
Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies 4
First‐Line Treatment of IGHV ‐Unmutated Chronic Lymphocytic Leukemia: A Network Meta‐Analysis of Targeted and Chemoimmunotherapy Regimens 2
From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management 2
High-dose ruxolitinib (25 mg twice daily) in myelofibrosis: feasibility, safety, and long-term treatment exposure in a real-world cohort 1
To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy 1
The Gut Microbiota in Hematologic Malignancies: Mechanisms, Clinical Associations, and Translational Opportunities 1
Totale 6.765
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.915
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.915
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202368 0 0 0 0 0 0 30 3 4 4 21 6
2023/2024593 9 14 121 90 53 90 29 20 20 9 21 117
2024/20251.380 53 107 33 72 66 63 32 67 202 138 139 408
2025/20264.725 485 260 409 317 735 327 533 226 397 454 313 269
Totale 6.766